Age-Related Macular Degeneration Therapeutic Pipel
Post# of 301275
NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- According to a new research report “Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.
Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analy...e-analysis
The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.
As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.
Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.
There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.
Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.
Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry...ion-market
Related Research
Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017
Factors such as emerging combination therapies and biomarker identification are driving the growth of the PI3K inhibitors pipeline. Combination therapies are being used to stop further cancer growth and kill the cancerous cells. Also, combining novel drugs against different signaling pathways as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.
https://www.psmarketresearch.com/market-analy...e-analysis
Venous Thromboembolism Therapeutics Pipeline Analysis, 2017
According to American Heart Association, Venous thromboembolism (VTE) collectively develops as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two life-threatening conditions. Venous thromboembolism is a common and preventable disease in which the clot formation occurs in the vein associated with Venous thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free from a vein wall, travels to the lungs and blocks some or all of the blood supply. Blood clots in the thigh are more likely to break off and travel to the lungs than the clots in lower leg or other parts of the body.
https://www.psmarketresearch.com/market-analy...e-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact: Kundan Kumar Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +1-888-778-7886 (USA/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com
(0)
(0)